फलो गर्नुहोस्
Englishनेपाली
← पछाडि
औषधि · अन्तरक्रिया

Octreotide — अन्तरक्रिया (Interactions)

अन्य औषधि, खाना र जडीबुटी उत्पादनले Octreotide को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Octreotide कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।

← पूरा Octreotide गाइडमा फर्कनुहोस्

⚠ सावधानी: The following drugs require monitoring and possible dose adjustment when used with octreotide acetate injection : cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Lutetium Lu 177 Dotatate Injection : Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose.

Octreotide को लेबलमा नाम भएका औषधिहरू

लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।

लेबलको खण्ड 7.1

Cyclosporine Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Concomitant administration of octreotide acetate injection with cyclosporine may decrease blood levels of cyclosporine and result in transplant rejection.

Insulin and Oral Hypoglycemic

Drugs Octreotide inhibits the secretion of insulin and glucagon. Therefore, blood glucose levels should be monitored when octreotide acetate injection treatment is initiated or when the dose is altered and anti-diabetic treatment should be adjusted accordingly.

लेबलको खण्ड 7.3

Bromocriptine Concomitant administration of octreotide and bromocriptine increases the availability of bromocriptine.

लेबलको खण्ड 7.4

Other Concomitant Drug Therapy Concomitant administration of bradycardia-inducing drugs (e.g., beta-blockers) may have an additive effect on the reduction of heart rate associated with octreotide. Dose adjustments of concomitant medication may be necessary.

Drug Metabolism Interactions Limited

Published data indicate that somatostatin analogs might decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH.

Lutetium Lu 177 Dotatate Injection

Octreotide competitively binds to somatostatin receptors and may interfere with the efficacy of lutetium Lu 177 dotatate. Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose.

Octreotide को लेबलले ४ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।

यहाँ नाम भएका औषधिका अन्तरक्रिया पृष्ठहरू

यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:

Octreotide को लेबलको पूरा अन्तरक्रिया खण्ड पढ्नुहोस्

The following drugs require monitoring and possible dose adjustment when used with octreotide acetate injection : cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Lutetium Lu 177 Dotatate Injection : Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose.

7.1 Cyclosporine Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Concomitant administration of octreotide acetate injection with cyclosporine may decrease blood levels of cyclosporine and result in transplant rejection.

7.2 Insulin and Oral Hypoglycemic Drugs Octreotide inhibits the secretion of insulin and glucagon. Therefore, blood glucose levels should be monitored when octreotide acetate injection treatment is initiated or when the dose is altered and anti-diabetic treatment should be adjusted accordingly.

7.3 Bromocriptine Concomitant administration of octreotide and bromocriptine increases the availability of bromocriptine.

7.4 Other Concomitant Drug Therapy Concomitant administration of bradycardia-inducing drugs (e.g., beta-blockers) may have an additive effect on the reduction of heart rate associated with octreotide. Dose adjustments of concomitant medication may be necessary. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs.

7.5 Drug Metabolism Interactions Limited published data indicate that somatostatin analogs might decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine) should therefore be used with caution.

7.6 Lutetium Lu 177 Dotatate Injection Octreotide competitively binds to somatostatin receptors and may interfere with the efficacy of lutetium Lu 177 dotatate. Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose.

Octreotide गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z

स्रोतU.S. FDA-approved label via DailyMed (label effective 16 Jan 2025) · NepalDoc medicine catalog · अमेरिकी लेबलिङ नेपालको DDA-स्वीकृत लेबलिङ र स्थानीय प्रिस्क्राइबिङ अभ्यासभन्दा फरक हुन सक्छ।

यो पृष्ठले Octreotide को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।

एपमा औषधि खोज्नुहोस् फार्मेसी खोज्नुहोस्
+ सुरक्षा जानकारी

यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।

यो औषधि सेयर गर्नुहोस्
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.